- Home
- MFIN vs CRBU Comparison
MFIN vs CRBU Comparison
Compare MFIN & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | CRBU |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 192.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MFIN | CRBU |
|---|---|---|
| Price | $9.56 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $10.75 |
| AVG Volume (30 Days) | 50.5K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | $0.02 | $10.93 |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $1.04 |
| 52 Week High | $11.00 | $3.53 |
Technical Indicators
Market Signals| Indicator | MFIN | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 41.92 |
| Support Level | $9.15 | $1.75 |
| Resistance Level | $9.87 | $2.09 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 46.91 | 7.98 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.